185 related articles for article (PubMed ID: 34351787)
1. Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer.
Barcenas CH; Song J; Murthy RK; Raghavendra AS; Li Y; Hsu L; Carlson RW; Tripathy D; Hortobagyi GN
JCO Clin Cancer Inform; 2021 Aug; 5():789-804. PubMed ID: 34351787
[TBL] [Abstract][Full Text] [Related]
2. A nomogram for predicting survival in patients with de novo metastatic breast cancer: a population-based study.
Zhao W; Wu L; Zhao A; Zhang M; Tian Q; Shen Y; Wang F; Wang B; Wang L; Chen L; Zhao X; Dong D; Zhang L; Yang J
BMC Cancer; 2020 Oct; 20(1):982. PubMed ID: 33046035
[TBL] [Abstract][Full Text] [Related]
3. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
[TBL] [Abstract][Full Text] [Related]
4. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
den Brok WD; Speers CH; Gondara L; Baxter E; Tyldesley SK; Lohrisch CA
Breast Cancer Res Treat; 2017 Feb; 161(3):549-556. PubMed ID: 28000014
[TBL] [Abstract][Full Text] [Related]
5. Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus.
Duan F; Song C; Ma Y; Jiang K; Xu F; Bi X; Huang J; Hong R; Huang Z; Lu Q; Yuan Z; Wang S; Xia W
Drug Des Devel Ther; 2021; 15():3463-3473. PubMed ID: 34408400
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?
Dawood S; Broglio K; Valero V; Reuben J; Handy B; Islam R; Jackson S; Hortobagyi GN; Fritsche H; Cristofanilli M
Cancer; 2008 Nov; 113(9):2422-30. PubMed ID: 18785255
[TBL] [Abstract][Full Text] [Related]
7. Construction and validation of prognostic nomogram for metaplastic breast cancer.
Li Y; Chen D; Xuan H; Dragomir MP; Calin GA; Meng X; Chen M; Jin H
Bosn J Basic Med Sci; 2022 Feb; 22(1):131-139. PubMed ID: 34247567
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand.
Lao C; Kuper-Hommel M; Elwood M; Campbell I; Edwards M; Lawrenson R
Breast Cancer; 2021 Mar; 28(2):387-397. PubMed ID: 33044617
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Peer PG; Tjan-Heijnen VC
Br J Cancer; 2015 Apr; 112(9):1445-51. PubMed ID: 25880008
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database.
Carausu M; Carton M; Darlix A; Pasquier D; Leheurteur M; Debled M; Mouret-Reynier MA; Goncalves A; Dalenc F; Verret B; Campone M; Augereau P; Ferrero JM; Levy C; Fumet JD; Lefeuvre-Plesse C; Petit T; Uwer L; Jouannaud C; Larrouquere L; Chevrot M; Courtinard C; Cabel L
ESMO Open; 2021 Jun; 6(3):100150. PubMed ID: 33984675
[TBL] [Abstract][Full Text] [Related]
11. Utilizing Data Visualization to Identify Survival and Treatment Differences Between Women With De Novo and Recurrent Metastatic Breast Cancer.
Gilbert A; Williams C; Azuero A; Burkard ME; Kenzik K; Garrett-Mayer E; Meersman S; Rocque G
Clin Breast Cancer; 2021 Aug; 21(4):292-301. PubMed ID: 33309481
[TBL] [Abstract][Full Text] [Related]
12. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer.
Yardley DA; Kaufman PA; Brufsky A; Yood MU; Rugo H; Mayer M; Quah C; Yoo B; Tripathy D
Breast Cancer Res Treat; 2014 Jun; 145(3):725-34. PubMed ID: 24706168
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract][Full Text] [Related]
14. Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients.
Giordano A; Egleston BL; Hajage D; Bland J; Hortobagyi GN; Reuben JM; Pierga JY; Cristofanilli M; Bidard FC
Clin Cancer Res; 2013 Mar; 19(6):1596-602. PubMed ID: 23340302
[TBL] [Abstract][Full Text] [Related]
15. A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer.
Prat A; Tsai YH; Pascual T; Paré L; Adamo B; Vidal M; Brasó-Maristany F; Galván P; Brase JC; Rodrik-Outmezguine V; Johnston S; Ciruelos E; Parker JS
Clin Cancer Res; 2020 Dec; 26(23):6141-6148. PubMed ID: 32962980
[TBL] [Abstract][Full Text] [Related]
16. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
17. Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer.
Kanjanapan Y; Lok SW; Gibbs P; De Boer R; Yeo B; Greenberg S; Barnett F; Knott L; Richardson G; Wong R; Nottage M; Collins IM; Torres J; Lombard J; Johns J; Harold M; Malik L
Breast Cancer Res Treat; 2020 Nov; 184(1):87-95. PubMed ID: 32779037
[TBL] [Abstract][Full Text] [Related]
18. The Difference in Prognostic Outcomes Between
Yamamura J; Kamigaki S; Fujita J; Osato H; Komoike Y
In Vivo; 2018; 32(2):353-358. PubMed ID: 29475920
[TBL] [Abstract][Full Text] [Related]
19. Establishing a predicted model to evaluate prognosis for initially diagnosed metastatic Her2-positive breast cancer patients and exploring the benefit from local surgery.
Lin H; Wu Y; Liang G; Chen L
PLoS One; 2020; 15(11):e0242155. PubMed ID: 33170907
[TBL] [Abstract][Full Text] [Related]
20. Immediate Breast Reconstruction in De Novo Metastatic Breast Cancer: An Analysis of 563 Cases Based on the SEER Database.
Chen H; Zhang M; Wang M; Zhang P; Bai F; Wu K
Clin Breast Cancer; 2019 Feb; 19(1):e135-e141. PubMed ID: 30497928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
